PubMed=15753399; DOI=10.1158/0008-5472.CAN-04-3625
Pohl G., Ho C.-L., Kurman R.J., Bristow R., Wang T.-L., Shih I.-M.
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
Cancer Res. 65:1994-2000(2005)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)